SOUTH PLAINFIELD, NJ and HACKENSACK, NJ -- (Marketwired) -- 06/28/13 -- GENEWIZ, Inc., leading global genomics service provider, and the John Theurer Cancer Center at Hackensack University Medical Center today announced a collaboration that will combine efforts towards the advancement of ovarian cancer biomarker discovery research.
This research collaboration will enable analysis of ovarian cancer samples for the identification of biomarkers predicting prognosis and chemotherapy outcomes for ovarian cancer. GENEWIZ will process and analyze clinical samples supplied by the John Theurer Cancer Center in CLIA-certified, CAP-accredited laboratories located at their global headquarters in South Plainfield, NJ.
"GENEWIZ's cutting-edge genomic analysis technologies and informatics capabilities, including our recently launched OncoGxOne Discovery ovarian cancer panel, enable us to comprehensively assay ovarian cancer-related genes for the detection of all types of genomic aberrations, including gene fusions and copy number variance (CNV), in addition to Indels and point mutations," stated Dr. Shihong Li, GENEWIZ Principal Investigator.
"Working with GENEWIZ offers the confidence of proven competencies in comprehensive genomic analysis for cancer research, as well as the benefit of having a CLIA-certified, CAP-accredited laboratory for working with our clinical samples," remarked Dr. K. Stephen Suh, Principal Investigator at the John Theurer Cancer Center at Hackensack University Medical Center. "We are excited to work together for the improvement of cancer care and women's health overall."
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Osaka, Japan.
About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at Hackensack University Medical Center is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer -- the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.
Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care, and medical expertise -- all under one roof. Physicians at John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information, please visit jtcancercenter.org.
115 Corporate Boulevard
South Plainfield, NJ 07080
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- GM to Stop Making Autos in Australia
- Selena Gomez, Shakira Among Top Hispanic Searches
- PhD Project Grooms Business Profs
- How Bitcoin and Other Cryptocurrencies Work
- Futures Fall, Holiday Spending and Unemployment Up
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Oil Nears $98 a Barrel